Rodenberg R, Spadafora D, Fitzpatrick S, Daly G, Lausch R, Barrington R
Invest Ophthalmol Vis Sci. 2024; 65(13):16.
PMID: 39504049
PMC: 11549926.
DOI: 10.1167/iovs.65.13.16.
Lei X, Gou Y, Hao J, Huang X
Front Oncol. 2024; 14:1375729.
PMID: 38725629
PMC: 11079285.
DOI: 10.3389/fonc.2024.1375729.
Silvestre R, Eitler J, Azevedo J, Tirapelle M, Fantacini D, de Souza L
Front Immunol. 2023; 14:1226518.
PMID: 37818365
PMC: 10561086.
DOI: 10.3389/fimmu.2023.1226518.
Fiuza-Luces C, Valenzuela P, Galvez B, Ramirez M, Lopez-Soto A, Simpson R
Nat Rev Immunol. 2023; 24(4):282-293.
PMID: 37794239
DOI: 10.1038/s41577-023-00943-0.
Tu W, Cao Y, Sun M, Liu Q, Zhao H
Front Med (Lausanne). 2023; 10:1209439.
PMID: 37727765
PMC: 10506410.
DOI: 10.3389/fmed.2023.1209439.
The PI3K-Akt-mTOR and Associated Signaling Pathways as Molecular Drivers of Immune-Mediated Inflammatory Skin Diseases: Update on Therapeutic Strategy Using Natural and Synthetic Compounds.
Roy T, Boateng S, Uddin M, Banang-Mbeumi S, Yadav R, Bock C
Cells. 2023; 12(12).
PMID: 37371141
PMC: 10297376.
DOI: 10.3390/cells12121671.
Pancancer Analysis Revealed the Value of RAC2 in Immunotherapy and Cancer Stem Cell.
Liu R, Li T, Zhang G, Jia Y, Liu J, Pan L
Stem Cells Int. 2023; 2023:8485726.
PMID: 37214785
PMC: 10198763.
DOI: 10.1155/2023/8485726.
Diminished cell proliferation promotes natural killer cell adaptive-like phenotype by limiting FcεRIγ expression.
Shemesh A, Su Y, Calabrese D, Chen D, Arakawa-Hoyt J, Roybal K
J Exp Med. 2022; 219(11).
PMID: 36066491
PMC: 9448639.
DOI: 10.1084/jem.20220551.
Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy.
Ruppel K, Fricke S, Kohl U, Schmiedel D
Front Immunol. 2022; 13:822298.
PMID: 35371071
PMC: 8971283.
DOI: 10.3389/fimmu.2022.822298.
Exercise Training and Natural Killer Cells in Cancer Survivors: Current Evidence and Research Gaps Based on a Systematic Review and Meta-analysis.
Valenzuela P, Saco-Ledo G, Santos-Lozano A, Morales J, Castillo-Garcia A, Simpson R
Sports Med Open. 2022; 8(1):36.
PMID: 35244811
PMC: 8897541.
DOI: 10.1186/s40798-022-00419-w.
Metabolic Disorders in Multiple Myeloma.
Gavriatopoulou M, Paschou S, Ntanasis-Stathopoulos I, Dimopoulos M
Int J Mol Sci. 2021; 22(21).
PMID: 34768861
PMC: 8584036.
DOI: 10.3390/ijms222111430.
Directly reprogrammed natural killer cells for cancer immunotherapy.
Kim H, Kim J, Seol B, Song C, Jeong J, Cho Y
Nat Biomed Eng. 2021; 5(11):1360-1376.
PMID: 34341536
DOI: 10.1038/s41551-021-00768-z.
Activated PI3Kinase Delta Syndrome-A Multifaceted Disease.
Thouenon R, Moreno-Corona N, Poggi L, Durandy A, Kracker S
Front Pediatr. 2021; 9:652405.
PMID: 34249806
PMC: 8267809.
DOI: 10.3389/fped.2021.652405.
TREM2 promotes natural killer cell development in CD3CD122NK1.1 pNK cells.
Lee H, Lee E, Yi J, Ji K, Kim S, Choi H
BMC Immunol. 2021; 22(1):30.
PMID: 33980160
PMC: 8114489.
DOI: 10.1186/s12865-021-00420-0.
The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression.
Rohrbacher L, Brauchle B, Wagner A, von Bergwelt-Baildon M, Bucklein V, Subklewe M
Front Immunol. 2021; 12:608625.
PMID: 33790890
PMC: 8005712.
DOI: 10.3389/fimmu.2021.608625.
Multi-cohort analysis of host immune response identifies conserved protective and detrimental modules associated with severity across viruses.
Zheng H, Rao A, Dermadi D, Toh J, Jones L, Donato M
Immunity. 2021; 54(4):753-768.e5.
PMID: 33765435
PMC: 7988739.
DOI: 10.1016/j.immuni.2021.03.002.
Metabolic Reprogramming Induces Immune Cell Dysfunction in the Tumor Microenvironment of Multiple Myeloma.
Wu S, Kuang H, Ke J, Pi M, Yang D
Front Oncol. 2021; 10:591342.
PMID: 33520703
PMC: 7845572.
DOI: 10.3389/fonc.2020.591342.
Single-cell transcriptome atlas of lung adenocarcinoma featured with ground glass nodules.
Lu T, Yang X, Shi Y, Zhao M, Bi G, Liang J
Cell Discov. 2020; 6:69.
PMID: 33083004
PMC: 7536439.
DOI: 10.1038/s41421-020-00200-x.
In silico investigation of heparanase-correlated genes in breast cancer subtypes.
Melo C, Prado H, Attie G, Ruiz D, Girao M, da Silva Pinhal M
Einstein (Sao Paulo). 2020; 18:eAO5447.
PMID: 33053017
PMC: 7531901.
DOI: 10.31744/einstein_journal/2020AO5447.
Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunity.
Sun P, Meng L
Acta Pharmacol Sin. 2020; 41(11):1395-1402.
PMID: 32939035
PMC: 7656798.
DOI: 10.1038/s41401-020-00500-8.